Vesilute Canada — 20 mg Lyophilized Vials
Peptide Bioregulator
Vesilute is a short synthetic peptide of the bioregulator class, supplied for laboratory research and associated with urinary-tract tissue models.
Mix & Match
1 vial — no vial discount yet.
Add 2 more vials for 5% off.
After that, 10% at 5 vials, 20% at 10 vials.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
Vesilute is a short synthetic peptide of the bioregulator class, supplied for laboratory research and associated with urinary-tract tissue models.
No primary study of this compound has been published, and its sequence is not established in the peer-reviewed literature.
Third-party tested for purity, ID, quantity.
Coming Soon
The certificate of analysis for the 20mg lot is being finalised and will be published here as soon as the lab returns it.
Vesilute is offered within the family of tissue-directed short peptides that emerged from the Russian bioregulator research programme. Unlike better-documented members of that family, no published work characterizes this compound by name, and no PubChem or PubMed record corresponds to it.
The references below describe the short-peptide class generally, including peptide regulation of cell differentiation and studies of related peptides in urinary bladder models. They should be read as class background, not as evidence about Vesilute.
Vesilute appears in the research market as part of the tissue-directed bioregulator series. It has no documented synthesis, characterization, or activity study of its own.
Related peptides in the same family have been examined in urinary bladder research models.
There is no compound-specific literature for Vesilute, and its sequence is unverified. The references below cover the short-peptide bioregulator class and studies of related peptides in bladder models.
3 of the 4 areas below are addressed directly by a paper cited on this page.
Addressed on this page by Khavinson 2020. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
No paper cited on this page reports on urinary, bladder or tissue. This heading marks where Vesilute is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Addressed on this page by Khavinson 2020. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Khavinson 2020. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
The references section of this page cites 1 primary paper published in 2020 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Vesilute is frequently listed as a peptide by suppliers in this market. It is not one. The structure published on this page is the compound's actual chemistry, and research on it should be read against its own class rather than against peptide literature.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for Vesilute, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
Vesilute is commonly described online in connection with faster healing from injury and improved recovery. In the research literature the same compound is filed under short-peptide bioregulator class research, urinary bladder tissue models (related peptides) and peptide-regulated cell differentiation.
The 1 paper cited on this page, published in 2020 describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Presented alongside compounds with decades of published research, as though the evidence base is comparable.
It is not. Vesilute rests on 1 cited paper (in 2020). A record that thin cannot support conclusions about mechanism, effect or safety, and the honest reading is that this compound has been studied very little rather than studied and validated.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Every lot of Vesilute is independently assayed before it is released, and the certificate for the lot shipped is published rather than summarised. Where a certificate for a current lot is not yet posted, the lot has not yet been released against it.
Researchers who buy Vesilute in Canada through Eppix Labs receive a batch-labelled vial whose certificate is published against that lot code, so the material can be matched to its analysis rather than to a generic specification.
Vesilute is supplied as lyophilized powder. It is not a peptide, and solvent behaviour follows from its own chemistry rather than from the aqueous-vehicle conventions that apply to peptide material — the published literature for this compound is the reference for solvent selection, not a general peptide protocol.
Dry storage below freezing and protection from light are the general controls. As with any lyophilized material, the powder frequently sits as a thin film at the base of the vial and is easy to mistake for an empty vial before inspection.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of Vesilute. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Related
Eppix Flash Sale −30%Peptides
Triple GIP / GLP-1 / Glucagon Agonist · 10, 20, 40 & 120 mg Retatrutide is a synthetic peptide developed for controlled laboratory research involving multi-receptor signaling systems. It is structurally designed to interact with GLP-1, GIP, and glucagon receptor pathways within experimental environments.
RETA-CA-26F-1099.637%
11.76 mg / 10 mg
$41.96$59.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
Dual GIP / GLP-1 Agonist · 10, 30 & 65 mg Tirzepatide is a synthetic peptide developed for controlled laboratory research involving dual incretin receptor signaling systems. It is structurally designed to interact with GLP-1 and GIP receptor pathways within experimental environments.
TIRZ-CA-26G-1099.634%
11.42 mg / 10 mg
$24.46$34.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
GLP-1 Receptor Agonist · 10 mg Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone involved in glucose-dependent signaling. It is developed for controlled laboratory investigation within regulated experimental environments.
10 mgSEMA-CA-26F-1099.504%
11.27 mg / 10 mg
$38.46$54.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
Selective Amylin Agonist (LY3841136) · 10 mg This product is supplied as eloralintide (LY3841136), a long-acting, selective amylin receptor agonist studied in research on metabolic and body-weight regulation.
10 mgELOR-CA-26G-1099.810%
12.42 mg / 10 mg
$101.46$144.95CAD
Flash sale ends in
